Recent Updates
Recently added Catalysts
ASND

ASCENDIS PHARMA A/S INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income / (Loss) for the Three

Key Takeaway: Table of Contents INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS Page Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income / (Loss) for the Three Months Ended March 31, 2018 and 2017 F-2 Unaudited Con

Full Press Release Details

Table of Contents

INDEX TO UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS
Page
Unaudited Condensed Consolidated Interim Statements of Profit or Loss and Other Comprehensive Income / (Loss) for the Three Months Ended March 31, 2018 and 2017 F-2
Unaudited Condensed Consolidated Interim Statements of Financial Position as of March 31, 2018 and December 31, 2017 F-3
Unaudited Condensed Consolidated Interim Statements of Changes in Equity at March 31, 2018 and 2017 F-4
Unaudited Condensed Consolidated Interim Cash Flow Statements for the Three Months Ended March 31, 2018 and 2017 F-5
Notes to the Unaudited Condensed Consolidated Interim Financial Statements F-6

Table of Contents

Unaudited Condensed Consolidated Interim Statements of Profit or
and Other Comprehensive Income / (Loss) for the Three Months Ended March 31
Consolidated
Notes 2018 2017
(EUR 000)
Revenue 4 28 372
Research and development costs (30,540 ) (20,608 )
General and administrative expenses (4,662 ) (3,325 )
Operating profit / (loss) (35,174 ) (23,561 )
Finance income 702 130
Finance expenses (7,010 ) (1,722 )
Profit / (loss) before tax (41,482 ) (25,153 )
Tax on profit / (loss) for the period 107 14
Net profit / (loss) for the period (41,375 ) (25,139 )
Other comprehensive income / (loss)
Items that may be reclassified subsequently to profit or loss:
Exchange differences on translating foreign operations (9 ) 4
Other comprehensive income / (loss) for the period, net of tax (9 ) 4
Total comprehensive income / (loss) for the period, net of tax (41,384 ) (25,135 )
Profit / (loss) for the period attributable to owners of the Company (41,375 ) (25,139 )
Total comprehensive income / (loss) for the period attributable to owners of the Company (41,384 ) (25,135 )
EUR EUR
Basic and diluted earnings / (loss) per share (1.07 ) (0.78 )
Number of shares used for calculation (basic and diluted) (1) 38,699,204 32,428,908

Table of Contents

Unaudited Condensed Consolidated Interim Statements of Financial
Notes March 31, 2018 December 31, 2017
(EUR 000)
Assets
Non-current assets
Intangible assets 3,495 3,495
Property, plant and equipment 2,461 2,557
Deposits 1,112 293
7,068 6,345
Current assets
Trade receivables 34 188
Other receivables 1,128 1,410
Prepayments 7,119 6,907
Income taxes receivable 1,067 778
Cash and cash equivalents 348,410 195,351
357,758 204,634
Total assets 364,826 210,979
Equity and liabilities
Equity
Share capital 7 5,577 4,967
Distributable equity 341,836 182,244
Total equity 347,413 187,211
Current liabilities
Trade payables and other payables 17,413 23,768
Total liabilities 17,413 23,768
Total equity and liabilities 364,826 210,979

Table of Contents

Unaudited Condensed Consolidated Interim Statements of Changes in
Distributable Equity
(EUR 000)
Share Capital Share Premium Foreign Currency Translation Reserve Share-based Payment Reserve Accumulated Deficit Total
Equity at December 31, 2017 4,967 422,675 (14 ) 22,793 (263,210 ) 187,211
Loss for the period (41,375 ) (41,375 )
Other comprehensive income / (loss), net of tax (9 ) (9 )
Total comprehensive income / (loss) (9 ) (41,375 ) (41,384 )
Share-based payment (Note 6) 4,679 4,679
Capital increase 610 209,415 210,025
Cost of capital increase (13,118 ) (13,118 )
Equity at March 31, 2018 5,577 618,972 (23 ) 27,472 (304,585 ) 347,413
Distributable Equity
(EUR 000)
Share Capital Share Premium Foreign Currency Translation Reserve Share-based Payment Reserve Accumulated Deficit Total
Equity at December 31, 2016 4,354 298,567 (79 ) 13,084 (139,313 ) 176,613
Loss for the period (25,139 ) (25,139 )
Other comprehensive income / (loss), net of tax 4 4
Total comprehensive income / (loss) 4 (25,139 ) (25,135 )
Share-based payment (Note 6) 2,705 2,705
Capital increase 11 633 644
Equity at March 31, 2017 4,365 299,200 (75 ) 15,789 (164,452 ) 154,827

Table of Contents

Unaudited Condensed Consolidated Interim Cash Flow Statements for
Three Months Ended March 31
Consolidated
Notes 2018 2017
(EUR 000)
Operating activities
Net profit / (loss) for the period (41,375 ) (25,139 )
Reversal of finance income (702 ) (130 )
Reversal of finance expenses 7,010 1,722
Reversal of tax charge (107 ) (14 )
Adjustments for:
Share-based payment 4,679 2,705
Depreciation and amortization 198 169
Changes in working capital:
Deposits (819 ) 1
Trade receivables 154 (91 )
Other receivables 282 (1,281 )
Prepayments (211 ) (3,662 )
Trade payables and other payables (6,364 ) 4,419
Deferred income
Cash flows generated from / (used in) operations (37,255 ) (21,301 )
Finance income received 702 130
Finance expenses paid (4 ) (25 )
Income taxes received / (paid) (183 ) (54 )
Cash flows from / (used in) operating activities (36,740 ) (21,250 )
Investing activities
Acquisition of property, plant and equipment (102 ) (377 )
Cash flows used in investing activities (102 ) (377 )
Financing activities
Capital increase 210,025 644
Cost of capital increase (13,118 )
Cash flows from / (used in) financing activities 196,907 644
Increase / (decrease) in cash and cash equivalents 160,065 (20,983 )
Cash and cash equivalents at January 1 195,351 180,329
Effect of exchange rate changes on balances held in foreign currencies (7,006 ) (1,698 )
Cash and cash equivalents at March 31 348,410 157,648
Restricted cash included in cash and cash equivalents 5,142 63

Table of Contents

Notes to the Unaudited Condensed Consolidated Interim Financial
Note 1 General Information
Ascendis Pharma A/S, together with its subsidiaries, is a biopharmaceutical company applying its innovative TransCon technology to build a
leading, fully integrated rare disease company. Ascendis Pharma A/S was incorporated in 2006 and is headquartered in Hellerup, Denmark. Unless the context otherwise requires, references to the Company, we, us and
our refer to Ascendis Pharma A/S and its subsidiaries.
The address of the Company s registered office is Tuborg
Boulevard 5, DK-2900, Hellerup, Denmark.
On February 2, 2015, the Company completed an
initial public offering, or IPO, which resulted in the listing of American Depositary Shares, or ADSs, representing the Company s ordinary shares, under the symbol ASND in the United States on The Nasdaq Global Select Market.
The Company s Board of Directors approved these unaudited condensed consolidated interim financial statements on May 30, 2018.
Note 2 Summary of Significant Accounting Policies
Basis of Preparation
condensed consolidated interim financial statements of the Company are prepared in accordance with International Accounting Standard 34, Interim Financial Reporting . Certain information and disclosures normally included in the
consolidated financial statements prepared in accordance with International Financial Reporting Standards ( IFRS ) have been condensed or omitted. Accordingly, these condensed consolidated interim financial statements should be read in
conjunction with the Company s annual consolidated financial statements for the year ended December 31, 2017 and accompanying notes, which have been prepared in accordance with IFRS as issued by the International Accounting Standards
Board, and as adopted by the European Union.
The preparation of financial statements in conformity with IFRS requires the use of certain
critical accounting estimates and requires management to exercise its judgment in the process of applying the Company s accounting policies. The areas involving a higher degree of judgment or complexity, or areas where assumptions and estimates
are significant to the condensed consolidated interim financial statements are disclosed in Note 3.
Changes in Accounting Policies
As of January 1, 2018, the Company has adopted IFRS 9, Financial Instruments , which introduces a new impairment model for
financial assets measured at amortized cost based on an expected credit loss model, which currently applies to the Company s bank deposits and trade receivables. The adoption of IFRS 9 had no material impact on the Company s financial
reporting. Further, the Company has adopted IFRS 15, Revenue from Contracts with Customers , which establishes a single, comprehensive framework for revenue recognition, based on a five-step model, which applies to the Company s
licensing agreements with multiple activities. IFRS 15 was adopted using the retrospective method with the cumulative effect of initially applying this standard recognized at the date of the initial application . The adoption of
IFRS 15 had no impact on the Company s financial reporting.
Except for the adoption of these two new standards, the accounting
policies applied when preparing these condensed consolidated interim financial statements have been applied consistently to all the periods presented, unless otherwise stated and are consistent with those of the Company s most recent annual
consolidated financial statements. A description of our accounting policies is provided in the Accounting Policies section of the audited consolidated financial statements as of and for the year ended December 31, 2017.
Note 3 Critical Accounting Judgments and Key Sources of Estimation Uncertainty
In the application of our accounting policies, we are required to make judgments, estimates and assumptions about the carrying amounts of
assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these
The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in
the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

Table of Contents

Notes to the Unaudited Condensed Consolidated Interim Financial Statements
Critical judgments made in the process of applying our accounting policies and that have the
most significant effect on the amounts recognized in our unaudited condensed consolidated financial statements relate to revenue recognition, share-based payment, internally generated intangible assets, and joint arrangements / collaboration
The key sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying
amount of assets and liabilities within the next financial year relate to impairment of goodwill and to recognition of accruals for manufacturing and clinical trial activities. There have been no changes to the application of significant accounting
estimates, and no impairment losses have been recognized during the first three months of 2018 or 2017.
The unaudited condensed
consolidated interim financial statements do not include all disclosures for critical accounting estimates and judgments that are required in the annual consolidated financial statements, and should be read in conjunction with the Company s
annual consolidated financial statements for the year ended December 31, 2017.
Consolidated
Three Months Ended March 31,
2018 2017
(EUR 000)
Revenue from the rendering of services 28 372
License income
Total revenue 28 372
Revenue from external customers (geographical)
USA 28 372
Total revenue 28 372
Note 5 Segment Information
We are managed and operated as one business unit. No separate business areas or separate business units have been identified in relation to
product candidates or geographical markets. Accordingly, we do not disclose information on business segments or geographical markets, except for the geographical information on revenue included in Note 4.
Note 6 Warrants and Share-based Payment
Pharma A/S has established warrant programs, equity-settled share-based payment transactions, as an incentive for all of our employees, members of our Board of Directors and select external consultants.
Warrants are granted by our Board of Directors in accordance with authorizations given to it by the shareholders of Ascendis Pharma A/S. As of
March 31, 2018, 6,487,812 warrants had been granted, of which 19,580 warrants have been cancelled, 1,600,845 warrants have been exercised, 2,168 warrants have expired without being exercised, and 207,328 warrants have been forfeited. As of
March 31, 2018, our Board of Directors was authorized to grant up to 1,531,592 additional warrants to our employees, board members and select consultants without pre-emptive subscription rights for the
shareholders of Ascendis Pharma A/S. Each warrant carries the right to subscribe for one ordinary share of a nominal value of DKK 1. The exercise price is fixed at the fair market value of our ordinary shares at the time of grant as determined by
our Board of Directors. The exercise prices of outstanding warrants under our warrant programs range from 6.48 to 54.10 depending on the grant dates. Vested warrants may be exercised in two or four annual exercise periods. Apart from
exercise prices and exercise periods, the programs are similar.

Table of Contents

Notes to the Unaudited Condensed Consolidated Interim Financial Statements
The following table specifies the warrant activity during the three months ended March 31, 2018:
Total Warrants Weighted Average Exercise Price EUR
Outstanding at December 31, 2017 4,621,154 17.62
Granted during the period 47,000 42.85
Exercised during the period
Forfeited during the period (10,263 ) 24.25
Expired during the period
Outstanding at March 31, 2018 4,657,891 17.86
Vested at the balance sheet date 2,298,231 12.38
Warrant Compensation Costs
Warrant compensation costs are determined with basis in the grant date fair value of the warrants granted and recognized over the vesting
Consolidated
Three months Ended March 31,
2018 2017
(EUR 000)
Research and development costs 2,386 1,289
General and administrative expenses 2,293 1,416
Total warrant compensation costs 4,679 2,705
Note 7 Share Capital
The share capital of Ascendis Pharma A/S consists of 41,523,765 shares at a nominal value of DKK 1, all in the same share class.
On February 26, 2018, the Company completed the sale and issuance of 4,539,473 ADSs in a public offering, increasing the Company s
share capital from 36,984,292 shares to 41,523,765 shares.
Note 8 Subsequent Events
No events have occurred after the balance sheet date that would have a significant impact on the results or financial position of the Company.
Last updated: May 30, 2018